article thumbnail

Investors put $400M into biotech licensing obesity drugs from China

BioPharma Drive: Drug Pricing

The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.

Licensing 356
article thumbnail

A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology

BioPharma Drive: Drug Pricing

But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes. Over the past 10 years, PD1-blocking medicines have transformed cancer care.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ADHD Drug Zenzedi Recalled Over Pill Mixup

Drugs.com

30, 2024 -- The maker of a drug used to treat ADHD and narcolepsy has recalled one lot of the medication after a pill mixup was discovered.The recall notice, issued by Azurity Pharmaceuticals Inc., TUESDAY, Jan. states that one lot of Zenzedi.

Drugs 347
article thumbnail

Lilly weight loss drug approved by FDA

BioPharma Drive: Drug Pricing

The pharmaceutical company will sell the GLP-1 drug, branded as Zepbound, at a list price about 20% lower than Novo Nordisk's competing drug Wegovy.

article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.

article thumbnail

The Importance of CDMO Flexibility: Adapting to the Ever-Changing Pharmaceutical Landscape

Drug Patent Watch

Let’s dive into the world of pharmaceutical outsourcing and explore why adaptability is the key to success. The Evolving Role of CDMOs in the Pharmaceutical Industry Gone are the days when CDMOs were mere service providers. Responding to Market Demands The pharmaceutical market is notoriously unpredictable.

article thumbnail

Maker Is Pulling Controversial ALS Drug Relyvrio Off the Market

Drugs.com

THURSDAY, April 4, 2024 (HealthDayNews) -- Following disappointing trial results, the maker of a controversial ALS drug said it is pulling the medication off the market. In a statement issued Thursday, Amylyx Pharmaceuticals said that Relyvrio.

Marketing 279